[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"high-altitude-polycythemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:high-altitude-polycythemia":53},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100640422","high-altitude-polycythemia-study-100640422",false,"NCT07600086","High-Altitude Polycythemia Study","Clinical Study on the Therapeutic Effect of Non-Invasive Ventilator in the Treatment of High-Altitude Polycythemia","NIV-HAPC","Inclusion Criteria:\n\n1. Diagnosed with high-altitude polycythemia (HAPC).\n2. Aged 18 years or older, with no gender restriction.\n3. Voluntarily participate in the study and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Disturbance of consciousness.\n2. Inability to independently clear airway secretions, with the risk of aspiration.\n3. Severe upper gastrointestinal bleeding.\n4. Hemodynamic instability.\n5. Upper airway obstruction.\n6. Un drained pneumothorax or mediastinal emphysema.\n7. Conditions that prevent mask wearing, such as facial trauma or deformity.\n8. Patient non-compliance.","ALL","18 Years",{"count":20,"type":21},70,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study aims to evaluate the clinical efficacy of non-invasive ventilation (NIV) in treating patients with high-altitude polycythemia (HAPC).\n\nParticipants will be enrolled according to the international diagnostic criteria for high-altitude polycythemia. The study will use both retrospective cohort and prospective study methods.\n\nAll participants will receive standard basic care. In addition, the intervention group will receive non-invasive ventilation treatment using either BiPAP or CPAP mode.\n\nKey measurements, including routine blood tests, liver function, renal function, uric acid, blood lipid profile, electrocardiogram and echocardiography, will be collected as primary and secondary outcome measures to assess the effects of the treatment.",[27,28],"High-altitude Polycythemia","HAPC","NOT_YET_RECRUITING","2026-05-14",{"date":32,"type":33},"2026-05-20","ACTUAL",{"date":35,"type":21},"2026-05",{"date":37,"type":21},"2028-12",{"name":39,"class":40},"Tibet Autonomous Region People's Hospital","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":22,"phases":49,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":58,"leadSponsor":60,"locationsCount":4},"100636190","phase-3-remote-ischemic-conditioning-for-high-altitude-polycythemia-in-high-altitude-immigrant-populations-100636190","NCT07562464","Remote Ischemic Conditioning for High Altitude Polycythemia in High-Altitude Immigrant Populations","Inclusion Criteria:\n\nAged ≥18 years, of either sex; Continuous residence in a high-altitude region (≥2500 meters) for more than 6 months, with no plan for long-term departure from the plateau during the study period; Meeting the diagnostic criteria for high-altitude polycythemia; Willing to provide written informed consent.\n\nExclusion Criteria:\n\nOther hematologic diseases, such as anemia or abnormal leukocytosis; Severe dysfunction of vital organs (e.g., heart, liver, kidney, lungs); Active malignancy, uncontrolled hyperthyroidism, active autoimmune disease, or poorly controlled diabetes mellitus; Pregnancy, planned pregnancy, or lactation for female participants; Contraindications to RIC (e.g., severe peripheral arterial disease, venous thrombosis, or soft tissue injury in the upper limbs); Any other condition deemed by the investigator to be unsuitable for participation in the study.",{"count":48,"type":21},222,[50],"PHASE3","This study is a multicenter, prospective, randomized, open-label, parallel-controlled clinical trial. The participants are adult patients with high-altitude polycythemia who have been long-term residents (for \\>6 months) in regions at an altitude of ≥2500 meters. Participants are randomly assigned to one of two groups: a conventional medication group and a remote ischemic conditioning (RIC) intervention group. The study aims to evaluate the effectiveness of a standardized 90-day RIC intervention, as an add-on to conventional medication, in managing high-altitude polycythemia.",[53],"High Altitude Polycythemia","2026-04-25",{"date":56,"type":33},"2026-05-01",{"date":32,"type":21},{"date":59,"type":21},"2028-06-30",{"name":61,"class":40},"Capital Medical University"]